-
Professor Yi Shuhua: Research on treatment and prognosis models go hand in hand, and diagnosis and treatment of mantle cell lymphoma is poised to take off
Time of Update: 2021-05-09
The results of many current clinical studies suggest that high-dose cytarabine-based chemotherapy in the first-line treatment does not bring survival benefits to patients with abnormal TP53, and the median overall survival after autologous hematopoietic stem cell transplantation consolidation therapy is only About 2 years.
-
Whole-process management of cardiotoxicity caused by anti-tumor chemotherapy: stratified screening, regular assessment and myocardial protection
Time of Update: 2021-05-09
Anti-tumor therapy cardiac risk assessment and full-process management baseline cardiac risk assessment In November 2020, the European Society of Cardiology (ESC) Oncology and Cardiology Committee and the American Heart Failure Society (HFSA) Oncology and Cardiology Research Group issued a position statement ——"Baseline Cardiovascular Risk Assessment of Cancer Patients Planning to Receive Cardiotoxic Cancer Treatment"[5].
-
JTO published the results of Professor Lu Shun and other niraparib maintenance treatment of SCLC; the world's first new indication of CD38 monoclonal antibody is about to be approved in China|Tumor News
Time of Update: 2021-05-09
*Only for medical professionals to read for reference, 1 minute a day, to give you professional "talking information" in the tumor circle! (If you need the original text of the literature, you can ad
-
Nature | First report of METL3 inhibitors with active in vivo, which can significantly inhibit the process of acute myeloid leukemia
Time of Update: 2021-05-09
On April 26, 2021, Tony Kouzarides, Konstantinos Tzelepis and Oliver Rausch from the University of Cambridge and Babraham Research Campus (Babraham Research Campus) published the study "Small molecule inhibition of METTL3 as a strategy against myeloid leukaemia" in Nature, The METL3 inhibitor STM2457 with in vivo activity was identified for the first time, and it was proved that STM2457 can significantly inhibit the process of acute myeloid leukemia.
-
Sub-Journal of Nature: Gu Zhen's team developed a "cell warehouse" to help CAR-T treat solid tumors
Time of Update: 2021-05-09
▎The editor of WuXi AppTec’s content team today published an interesting study in the sub-issue of Nature Biomedical Engineering: Professor Gu Zhen’s team from Zhejiang University developed a The "cell reservoir" (cell reservoir) immune cell local slow and controlled release technology has verified in animal models that this technology can significantly enhance the efficacy of CAR-T cells against solid tumors.
-
A+T regimen can change the treatment practice of patients with unresectable liver cancer in China; the first-line treatment of esophageal squamous cell carcinoma with teriprizumab in Phase III study is successful
Time of Update: 2021-05-09
On April 23, Liver Cancer reported IMbrave150 study Chinese subgroup data showed that for patients with unresectable hepatocellular carcinoma (HCC) who have not received systemic treatment, Compared with sorafenib, atelizumab + bevacizumab (hereinafter referred to as A+T) has clinically significant improvements in overall survival (OS) and progression-free survival (PFS).
-
2021 CSCO BC | Professor Tao Wang: Best of BCC 2021 Adjuvant Therapy Hotspot Interpretation
Time of Update: 2021-05-09
Gallen experts commented that "clinical performance meets the low risk and/or recurrence scores of MINDACT, TAILORx, RxPONDER and similar experiments "Whether postmenopausal patients with ≤25 should receive chemotherapy" is opposed to the non-screening question.
-
An overview of the article: 2021 CSCO Small Cell Lung Cancer Guidelines Update Key Points
Time of Update: 2021-05-09
"The ALTER1202 study update at the ASCO conference in 2020 shows that Anlotinib can significantly improve the PFS and OS of patients with relapsed SCLC within 3 months of second-line treatment.
-
Prof. Chunfang Hao | 2021 CSCO BC Diagnosis and Treatment Guidelines Update: Update Points and Progress of HR Positive Advanced Breast Cancer
Time of Update: 2021-05-09
Evidence-based evidence-based AI+CDK4/6 inhibitor PALOMA-2 study compared pipercillil+letrozole vs placebo+letrozole for postmenopausal ER+, HER2- advanced breast cancer patients Efficacy, the results showed that the median progression-free survival (PFS) of the piperacillil group was significantly better than that of the placebo group (30.
-
Quick question and answer: 5 questions to understand the manifestations and diagnosis of prostate cancer
Time of Update: 2021-05-09
Answer: B When the PSA level is >10ng/ml, the histological manifestations are at high risk ( Gleason ≥ 7 points), or when the clinical examination shows advanced disease, the patient is most likely to undergo CT scan and bone scan.
-
Professor Lin Shen and Professor Zhang Xiaotian: CheckMate-649 "Chinese Answer Sheet" refreshes history, opening a new stage for the first-line treatment of gastric cancer
Time of Update: 2021-05-09
CheckMate-649 is the study with the largest number of patients in the field of advanced gastric cancer so far, and it is also the first global study that surpasses chemotherapy to achieve significant overall survival benefits in the first-line treatment of HER2-negative gastric cancer in more than ten years; this announcement The data from the Chinese population is the first and so far only Chinese subgroup result from a Phase III study of first-line immunotherapy for gastric cancer.
-
FDA update | Accelerated approval of loncastuximab tesirine-lpyl for the treatment of patients with large B-cell lymphoma
Time of Update: 2021-05-09
15 mg/kg every 3 weeks; in the subsequent treatment cycles, patients received loncastuximab tesirine-lpyl 0.
15mg/kg every 3 weeks, and in the subsequent treatment cycles, receive loncastuximab tesirine-lpyl 0.
-
Take off the colored glasses to let cancer patients get better treatment
Time of Update: 2021-05-09
More than twenty experts and scholars from the four major domestic anesthesia-related professional fields, representatives of member units of the Anesthetic Association and Xinhua News Agency, Media representatives from China Daily and China Net discussed the standardized management, correct use of opioids, and the satisfaction of patients' needs for pain relief.
-
The 2021 version of the CSCO ICI guidelines was released, Sintilimab wins the four recommendations of the guidelines
Time of Update: 2021-05-09
Professor Wang Baocheng: According to the clinical research data based on the Chinese population, the adjustment of the new immune drug indication recommendation is the top priority of this guideline update.
-
The open operation of gene family tumor prognosis research
Time of Update: 2021-05-09
546), which is mainly based on the expression characteristics of STEAP family genes for prognostic and molecular typing of glioblastoma (GBM).
The prognostic analysis of family genes is one of the very friendly starting points for Shengxin Xiaobai.
How did this article complete the bioinformatics analysis?
-
Professor Luqun Wang: The current status of treatment and research progress of classic Hodgkin's lymphoma
Time of Update: 2021-05-09
Because the current traditional chemotherapy regimens still cannot fully meet the clinical needs of cHL, Professor Luqun Wang has explored the application of new targeted drugs in cHL in recent years.
-
Reactivate the immune response of PD-1 refractory patients!
Time of Update: 2021-05-09
In the cohort that received 3 injections (n=6), 60% (4/6) of the patients achieved considerable remission, of which 3 received PD-1 treatment 30 days ago, which means that PVSRIPO can be restarted/activated Immune response of PD-1 refractory patients.
-
2021 AACR | Repetinib China Data Appears on the World's Top Cancer Research Arena
Time of Update: 2021-05-09
This study was led by the team of Professor Lin Shen from Peking University Cancer Hospital, and explored the pharmacokinetic (PK) characteristics of repetinib and its active metabolites in patients with gastrointestinal stromal tumor (GIST) in China.
-
2021 version of CSCO gastric cancer guidelines update: neoadjuvant chemotherapy for stage Ⅲ patients becomes grade Ⅰ recommendation
Time of Update: 2021-05-09
2 Comprehensive treatment of gastric cancer 1) The overall treatment strategy Table 1 The overall treatment strategy for the comprehensive treatment of non-metastatic gastric cancer recommends that patients with stage III (cT3-4aN1-3M0) non-esophageal gastric junction cancer (cT3-4aN1-3M0) suitable for surgery will be treated as "laparoscopic exploration (Class 1B) Evidence), neoadjuvant chemotherapy + gastrectomy D2 + adjuvant chemotherapy (Class 1B evidence)" changed from level II recommendation to level I recommendation.
-
Cases Shenghui | Breaking with traditional treatments, anti-angiogenesis combined with immunity helps drive long-term survival of gene-negative advanced NSCLC
Time of Update: 2021-05-09
Recombinant human endostatin + chemotherapy + immunotherapy provides new treatment options for non-small cell lung cancer (NSCLC) patients with negative driver genes.
